Atherosclerosis Research

Atherosclerosis is a disease of the arterial system that is characterized by the accumulation of fatty deposits within arterial walls, known as 'atherosclerotic plaques'.

Atherosclerosis Research Products Targets

Products for Atherosclerosis Research - Page 9

Cat.No. Product Name Information/Activity
BCN2568 Mevastatin Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment.
BCC3842 Pitavastatin Calcium Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
BCC2321 Pravastatin sodium Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
BCN2569 Simvastatin HMG-CoA reductase inhibitor,Simvastatin is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM in cell-free assays.
BCC7530 SR 12813 SR12813 is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC50 value of 0.85 μM.
BCC7576 BAY-u 9773 Dual CysLT1 and CysLT2 antagonist
BCC7244 Cinalukast 128312-51-6
BCC7310 FPL 55712 40785-97-5
BCC7334 MK 571 MRP1 inhibitor; also CysLT1 (LTD4) inverse agonist
BCC4680 Montelukast Sodium Montelukast (sodium) (MK0476) is a potent, selective CysLT1 receptor antagonist.